Media contact: Stéphanie Bardon – communication@genethon.fr – 01.69.47.12.78
June 21, 2017
New partnership for the treatment of Duchenne muscular disease (DMD)
Sarepta Therapeutics, a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, and Genethon, have signed a gene therapy research collaboration to jointly develop treatments for Duchenne… (read more)
April 5, 2017
New step towards the treatment of myotubular myopathy: gene therapy restores strength and prolongs lives in affected dogs
May 15, 2015
ASGCT 18th Annual Meeting 2015: Ana Buj Bello receives the Outstanding New Investigator Award
May 13, 2015
Selecta and Genethon Collaborate to Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform
May 7, 2015
Evidence of efficacy of gene therapy in rodents affected by a rare genetic liver disease, Crigler-Najjar syndrome
April 21, 2015
New gene therapy success in a rare disease of the immune system: Wiskott-Aldrich syndrome
November 10, 2014
Effectiveness of innovative gene therapy treatment demonstrated in canine model of Duchenne muscular dystrophy
March 11, 2014
GENETHON and ESTEVE announce agreement to manufacture the gene therapy for the treatment of Sanfilippo Syndrome
February 5, 2014
Audentes Therapeutics and Genethon Announce Agreement to Develop Treatment for Severe Genetic Disease X‐Linked Myotubular Myopathy
January 23, 2014
Efficacy of gene therapy demonstrated in canine and murine models of myotubular myopathy
June 27, 2013
